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Background: Acute renal failure is a common complication of cardiac surgery, with oxidants 
found to play an important role in renal injury. We therefore assessed whether the supplemental 
antioxidant vitamin E and the inhibitor of xanthine oxidase allopurinol could prevent renal 
dysfunction after coronary artery bypass graft (CABG) surgery.
Methods: Of 60 patients with glomerular filtration rate (GFR)  60 mL/min scheduled to 
undergo CABG surgery, 30 were randomized to treatment with vitamin E and allopurinol for 
3–5 days before surgery and 30 to no treatment. Serum creatinine levels and potassium and 
creatinine clearances were measured preoperatively and daily until day 5 after surgery.
Results: The patients consisted of 31 males and 29 females, with a mean age of 
63 ± 9 years. After surgery, there were no significant differences in mean serum creatinine 
(1.2 ± 0.33 vs 1.2 ± 0.4 mg/dL; p = 0.43) concentrations, or creatinine clearance (52 ± 12.8 
vs 52 ± 12.8 mL/min; p = 0.9). The frequency of acute renal failure did not differ in treatment 
group compared with control (16% vs 13%; p = 0.5). Length of stay in the intensive care 
unit (ICU) was significantly longer in the control than in the treated group (3.9 ± 1.5 vs 
2.6 ± 0.7 days; p  0.001).
Conclusion: Prophylactic treatment with vitamin E and allopurinol had no renoprotective 
effects in patients with pre-existing renal failure undergoing CABG surgery. Treatment with 
these agents, however, reduces the duration of ICU stay.
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Introduction
Acute renal failure (ARF) is a common and dangerous complication of cardiac surgery, 
especially after surgery for cardiac coronary artery bypass graft (CABG),1 obstructive 
jaundice,2 and aortic aneurysm.3 ARF frequently arises because of decreased tissue 
perfusion, ischemia, adverse effects of free radicals,4 and blood vessel constriction 
stimulating the release of angiotensins such as endothelins.5 ARF following CABG has 
been found to increase mortality, morbidity, and intensive care unit (ICU) stay, with 
some patients requiring dialysis.6,7 To date, no effective prophylaxis has been found to 
prevent ARF. Among the agents that have been tested are calcium channel blockers,8,9 
anti-endothelin,10–12 theophylline,13,14 prostaglandin E1,15 low-dose dopamine,16–19 
intercellular adhesion molecule 1 (ICAM 1),20–22 platelet-activating factor (PAF),23,24 
and alpha melanocyte-stimulating hormone (αMSH),25,26 but results have not been 
satisfactory. As ischemia is involved in ARF after CABG, we assessed the effects of 
the supplemental antioxidant vitamin E and the inhibitor of xanthine oxidase allopurinol 
in the prophylaxis of ARF.Vascular Health and Risk Management 2009:5 490
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Materials and methods
The study involved patients with AFR undergoing CABG 
between March 2006 and March 2008. Inclusion crite-
ria included age 18 years, glomerular filtration rate 
(GFR)  60 mL/min, and no prior use of allopurinol or vitamin 
E. Exclusion criteria included nonelective emergency surgery, 
history of dialysis, allergy to vitamin E or allopurinol, and use 
of radio contrast media within three months prior to surgery. 
Patients were randomized to receive 100 units vitamin E four 
times per day and 100 mg allopurinol twice daily for three to 
five days prior to elective surgery, or to no treatment. None 
of patients were treated with these drugs before they were 
enrolled in the study. Patients in both groups were in the 
surgical ward and ICU of a cardiac super-specialization center 
and were treated under similar conditions. To prevent bias, 
the surgeons, nurses, and laboratory technicians were blinded 
to patient assignment. All patients received 1–2 L of normal 
saline before surgery to prevent dehydration. The study pro-
tocol was approved by our Institutional Ethics Committee, 
and all patients provided informed consent.
We assessed baseline demographic characteristics, 
including age, gender, body mass index (BMI), blood 
pressure, and history of cigarette smoking, history of 
diabetes, and any previous myocardial infarction (MI). 
Serum creatinine and potassium concentrations were 
measured one day before surgery and daily for five days 
after surgery using standard laboratory methods. Creatinine 
clearance (CCr) was calculated using the Cockcroft–Gault 
equation [CCr (mL/min) = (140 – age) × lean body weight 
(kg)/Cr (mg/dL) × 72] for men, with multiplication 
by 0.85 required for women. ARF was defined as a fall in 
GFR by 25%. Other surgery-related parameters included 
the presence of arrhythmia during and after surgery, length 
of surgery, left ventricular ejection fraction (EF) before and 
after surgery, duration of time on-pump, use of a defibril-
lator, duration of aortic clamp (in minutes), episodes of 
hypotension (systolic blood pressure 90 mm Hg) during 
surgery, and need for dopamine and dobutamine infusion 
during and after operation. We also assessed the duration 
(in days) of ICU stay, mortality rate, and any adverse effects 
of allopurinol and Vitamin E.
statistical analysis
Data are expressed as means ± standard deviations (SDs). 
Student’s t-test and the Mann–Whitney U test for unpaired 
data, or chi-square analysis, were used as appropriate to 
assess between-group differences. The SPSS 15 software pro-
gram (SPSS Inc., Chicago, IL) was used for all analyses.
Results
During the study period, from March 13, 2006 until March 21, 
2008, a total of 70 patients met our initial inclusion criteria. 
Of these, 10 were excluded, two because of a history of 
dialysis, three because of a history of injection with radio 
contrast media during the previous month, and five because 
of a history of allopurinol usage. Of the remaining 60 patients 
(31 males, 29 females), 30 were randomized to treatment 
with vitamin E and allopurinol and 30 to no treatment. The 
baseline demographic and clinical characteristics of the two 
groups were similar (Table 1).
After surgery, renal function, hemodynamic condition, 
ICU stay, and other parameters were compared between the 
two groups (Table 2). We found that GFR, serum creati-
nine concentration and the frequency of ARF did not differ 
significantly in the two groups. In contrast, length of stay in 
the ICU was significantly lower in the treatment group. For 
six months following surgery, no patient in either group died 
Table 1 Baseline clinical and demographic characteristics of patients 
in the control and treatment groups
Variablea Treatment 
group
Control group p valueb
Age 65 ± 9.5 years 61 ± 7.90 years 0.103
sex (M/F) 17/13 14/16 0.4
BMi 24.4 ± 3.22 24.1 ± 2.53 0.77
DM (no.) 11 18 0.71
HTN (no.) 14 18 0.59
History of Mi (no.) 17 11 0.108
smoking (no.) 11 4 0.016
Duration of 
operation (h)
3.6 ± 0.56 3.2 ± 0.83 0.169
Duration of aortic 
clamp (min)
32.5 ± 13.33 24.3 ± 9.76 0.185
Pump on (no.) 25 18 0.31
Preoperation eF 44.7 ± 12.29 49.4 ± 12.6 0.354
Preoperation 
serum cr (mg/dL)
1.3 ± 0.45 1.3 ± 0.53 0.918
Preoperation 
serum potassium 
(meq/L)
4.6 ± 0.48 4.2 ± 0.66 0.019
Preoperation ccr 
(mL/min)
48 ± 10 50 ± 10.3 0.412
Urine volume (mL) 1689.1 ± 
921.20
1530.0 ± 554.43 0.518
Notes: aNormal distribution of continuous variables was proven by Kolmogorov–smirnov; 
bBy a Bonferroni correction, a p value  0.00333 was considered significant.
Abbreviations: BMi, body mass index; DM, diabetes mellitus; HTN, hypertension; Mi, 
myocardial infarction; eF, ejection fraction; cr, creatinine; ccr, creatinine clearance; 
h, hour; min, minute.Vascular Health and Risk Management 2009:5 491
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or required dialysis. Only one patient receiving allopurinol 
had skin lesions, on the last day of treatment.
Discussion
We found that the combination of allopurinol and vitamin 
E did not have a significant effect after CABG on the renal 
function of patients with chronic renal failure. Among the 
possible causes of ARF after CABG are decreased tissue 
perfusion, ischemia, and free radical generation.4 To our 
knowledge, this study is the first to assess the effect of simul-
taneous treatment with allopurinol and vitamin E on kidney 
function in patients with pre-existing renal failure.
Allopurinol was selected as the choice of xanthine oxidase 
inhibitor because of the effects of this chemical on the ischemic 
process. For example, the blood concentrations of xanthine 
and hypoxanthine in CABG patients treated with either 
pump-on or pump-off procedures were shown to be signifi-
cantly higher after than before surgery.4 Although these levels 
were higher in pump-on than in pump-off patients, the highest 
concentrations were observed in cases admitted to the ICU. 
In addition, Allopurinol inhibition of xanthine oxidase may 
have an impact on lesions of ischemia-reperfusion, a poten-
tial occurrence in CABG surgery, and a condition in which 
xanthine oxidase has clearly been implicated.27 The potential 
effect of decreasing urate levels of allopurinol could have the 
therapeutic effect. However, we did not measure urate level 
and it is a limitation of the study.
Although no prior studies have evaluated whether 
allopurinol might prevent ARF in humans, the xanthine 
oxidase inhibitor oxypurinol did not prevent decreased 
renal function in rats, which may be because of the effect 
of oxypurinol to prevent the proliferation of nephron 
tubular cells.28 Similarly, in our study, the lack of effect of 
allopurinol on renal function may be related to drug antip-
roliferative effects on tubular cells.28
Patients receiving allopurinol were also treated with 
the antioxidant vitamin E to determine if these two agents 
might show an additive effect in preventing renal dysfunc-
tion in patients with ischemia. In rats, the lipid-soluble 
antioxidant α-tocopherol was shown to reduce oxidative 
stress, thus decreasing chronic renal failure.29 Vitamin E 
may prevent acute decreases in renal function induced by 
ischemia, contrast media, or drugs.30 In pigs, the combination 
of vitamins E and C after cisplatin caused significant 
increases in renal total superoxide scavenger activity; this, 
in turn, strengthens the renal antioxidant system, eliminates 
oxidation reactions, and prevents cisplatin-induced kidney 
failure.31 Vitamin E has also been found to prevent acute 
tubular necrosis following glycerol administration in rats,32 
and to prevent damage following renal ischemia.33 Roberts 
and colleagues34 have shown that a vitamin E treatment period 
of at least 16 weeks and 800 units/day was necessary for the 
significant increase in plasma concentrations of vitamin E. 
However we only used 3–5 days and 400 units of vitamin E. 
Therefore, it may be that the lack of effects seen here is due 
to insufficient antioxidants.
We did not administer vitamin E and allopurinol after 
surgery due to their possible lack of effect on renal function. 
Therefore, we suggest postsurgical administration of these 
drugs in further studies.
Various clinical trials have assessed the ability of 
different interventions to prevent ARF after CABG. The 
antioxidant N-acetylcysteine was found to have no effect in 
preventing ARF in cardiac patients,35 or in reducing the rate 
Table 2 clinical and paraclinical state of patients during and after surgery in the treatment and control groups
Variablea Treatment group Control group P valueb
Postoperation serum potassium (meq/L) 4.4 ± 0.30 4.3 ± 0.36 0.784
Postoperation serum creatinine (mg/dL) 1.2 ± 0.33 1.2 ± 0.40 0.435
Postoperation ccr (mL/min) 52.5 ± 12.84 52.3 ± 12.89 0.952
Postoperation ARF (no.) 5 4 0.5
Postoperation eF 44 ± 10.9 45 ± 10.4 0.74
Received dopamine infusionc (no.) 8 5 0.65
Hypotension (systolic BP  90 mm Hg)c (no.) 1 6 0.034
Arrhythmiac (no.) 12 18 0.56
icU stay (day) 2.6 ± 0.75 3.9 ± 1.54 0.000d
Notes: aNormal distribution of continuous variables was proven by Kolmogorov–smirnov; bBy a Bonferroni correction, a p value  0.00555 was considered significant; 
cDuring surgery; dA parametrical test (student’s t-test) was performed. However, a nonparametrical test (Mann–Whitney U test) was also performed and a P value of 0.004 
was obtained.
Abbreviations: eF, ejection fraction; ccr, creatinine clearance; min, minute; ARF, acute renal failure; icU, intensive care unit.Vascular Health and Risk Management 2009:5 492
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of renal failure in patients undergoing heart and/or aortic 
surgery.36–38 The renal function of on-pump CABG patients 
was improved by leukodepletion, which prevented tubule 
destruction,39 and infusion of sodium nitroprusside resulted 
in improved renal function in cardiac patients.40 As hydration 
prior to surgery has been found to prevent renal damage,41 
our patients were infused with 1–2 L of normal saline to 
prevent confounding the effects of dehydration with those 
of allopurinol and vitamin E. Calcium channel blockers, 
such as diltiazem42 and verapamil,43 have been shown to 
increase urine output and to maintain tubular integrity after 
cardiac surgery, without significantly affecting the GFR. The 
selective dopamine receptor fenoldopam has been found to 
maintain creatinine clearance in the 0–4 h and 4–8 h intervals 
after CABG.44 Although dopamine has been used to prevent 
ARF, this drug has not been shown to have any effect.19,45,46 
The ability of the α2-adrenergic receptor clonidine to prevent 
renal dysfunction in cardiac surgery patients may result from 
a reduction in the sympathetic nervous system response to 
CABG surgery.47 In a randomized study, simultaneous infu-
sion of nifedipine and maintenance of the hemodynamic state 
resulted in preservation of GFR and creatinine clearance after 
cardiac surgery.48
We found that duration of ICU stay was significantly 
shorter in the treatment group than in the control patients. 
In addition to a renoprotective effect, fenoldopam reduced 
the duration of ICU stay compared with placebo,49 a finding 
similar to ours. Another randomized study showed that 
N-acetylcysteine had no effect on renal function, duration 
of mechanical ventilation, postsurgical mortality, or required 
dose of dopamine.50
Although the mechanism of action by which the 
combination of allopurinol and vitamin E reduces ICU stay 
is not known, the antioxidant and xanthine oxidase inhibi-
tion effects of these drugs may decrease the amount of free 
radicals after surgery. In a finding similar to our study, 
Bartels and colleagues51 showed that length of ICU stay was 
significantly shorter in the vitamin E treatment group than 
in the placebo group. Their explanation was that vitamin E 
could reduce the impact of ischemia and reperfusion injury 
in liver surgery. Goode and colleagues52 also found that 
decreased tocopherol (vitamin E) plasma concentrations 
in patients admitted to the ICU resulted in enhanced free 
radical activity.
Although the benefit effects of antioxidant and xanthine 
oxidase inhibitor were mentioned above, the adverse effects 
of radical scavenger on immune system have been reported. 
Remer and colleagues53 showed that nitric oxide played an 
important role in the control of brain infection with listeria 
and administration of radical scavenger resulted in rapid death 
of the treated animals. We did not compare the frequency of 
the infectious diseases in two groups. This subject should be 
considered in further studies.
We reported skin lesion in one patient receiving 
allopurinol. However, several other potentially severe 
adverse reactions associated with allopurinol administration 
such as Stevens–Johnson syndrome and toxic epidermal 
necrolysis.54 On the other hand, large doses of vitamin E 
increase mortality.55 Therefore, the risk and benefit ratio of 
this treatment should be considered.
Conclusion
We found that the combination of vitamin E and allopurinol 
at the selected dose had no effect on renal function. Future 
studies, including patients with lower GFRs or higher 
creatinine levels, may show that antioxidants have significant 
effects on renal function. Allopurinol and vitamin E have a 
significant positive role in reducing the duration of ICU stay 
in CABG patients.
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